Oscotec and KT&G jointly to develop osteoporosis drugs.
Published: 2006-01-02 06:52:00
Updated: 2006-01-02 06:52:00
Oscotec and KT&G agreed for a joint development of OPG secretion stimulant, a new drug candidate for the treatment of osteoporosis and arthritis, and to assign its preclinical test to Quintiles, a UK clinical research company, some times during the first half of 2006.
OPG (osteoprotegerin) is ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
